Lots and lots of updates from the past weekend's ASCO annual meeting.

1. ADRIATIC (consolidation durvalumab in limited stage SCLC)

2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma)

3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer)

4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer)

5. TRANSMET (liver transplantation in colon cancer with liver mets)

6. Eposec (FLOT > CROSS in adenocarcinoma of the esophagus)

7. LAURA (forever osimertinib in stage III EGFR-mutated NSCLC post-chemoRT)

8. CROWN (5 year update of lorlatinib in ALK+ NSCLC)

9. Destiny Breast-06 (T-DXd vs. chemo in HER-2 low and "ultra" low MBC who haven't received chemo in metastatic setting)

10. ASC4FIRST (Asciminib first line in CML. Funny title, amirite?)